Evidence map›Paper›PMID 37073794›Full record

Trial reportTherapeutic advances in respiratory disease

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis.

Todd L Astor, Hilary J Goldberg, Laurie D Snyder, Andrew Courtwright, Ramsey Hachem, Tahuanty Pena, Lorenzo Zaffiri, Gerard J Criner, Marie M Budev, Tany Thaniyavarn and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04316780 (Impact of Pre-transplant Anti-fibrotic Therapy for Idiopathic Pulmonary Fibrosis Upon Lung Transplant Outcomes), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04316780 completednot on this map

Impact of Pre-transplant Anti-fibrotic Therapy for Idiopathic Pulmonary Fibrosis Upon Lung Transplant Outcomes

TypeobservationalSponsorSteward St. Elizabeth's Medical Center of Boston, Inc.Ran2019 to 2020Enrolled320ConditionsIdiopathic Pulmonary FibrosisArmsRetrospective observational study- no intervention to occur.
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

Todd L AstorDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
Hilary J GoldbergDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Laurie D SnyderDivision of Pulmonary, Allergy and Critical Care Medicine, Duke University, Durham, NC, USA.
Andrew CourtwrightDivision of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA, USA.
Ramsey HachemDivision of Pulmonary and Critical Care Medicine, Washington University, St. Louis, MO, USA.
Tahuanty PenaDivision of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, IA, USA.
Lorenzo ZaffiriDivision of Pulmonary, Allergy and Critical Care Medicine, Duke University, Durham, NC, USA.
Gerard J CrinerDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Marie M BudevRespiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
Tany ThaniyavarnDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Thomas B LeonardBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Shaun BenderBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Aliaa BarakatILD Collaborative, Boston, MA, USA.
Janis L BreezeTufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Peter LaCameraDivision of Pulmonary, Critical Care and Sleep Medicine, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, USA.ORCID 0000-0002-4317-3708
Boehringer Ingelheim (United States) · USBrigham and Women's Hospital · USDuke University · USCleveland Clinic · USMassachusetts General Hospital · USSt. Elizabeth's Medical Center · USTemple University · USTufts University · USUniversity of Iowa · USUniversity of Pennsylvania · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases the risk of complications in patients with idiopathic pulmonary fibrosis.

objectivesTo investigate whether the time between discontinuation of anti-fibrotic therapy and lung transplant in patients with idiopathic pulmonary fibrosis affects the risk of complications.

methodsWe assessed intra-operative and post-transplant complications among patients with idiopathic pulmonary fibrosis who underwent lung transplant and had been treated with nintedanib or pirfenidone continuously for ⩾ 90 days at listing. Patients were grouped according to whether they had a shorter (⩽ 5 medication half-lives) or longer (> 5 medication half-lives) time between discontinuation of anti-fibrotic medication and transplant. Five half-lives corresponded to 2 days for nintedanib and 1 day for pirfenidone.

resultsAmong patients taking nintedanib (

conclusionAnastomotic and sternal dehiscence only occurred in patients with idiopathic pulmonary fibrosis who discontinued anti-fibrotic therapy < 5 medication half-lives before transplant. The frequency of other intra-operative and post-transplant complications did not appear to differ depending on when anti-fibrotic therapy was discontinued. REGISTRATION: clinicaltrials.gov NCT04316780: https://clinicaltrials.gov/ct2/show/NCT04316780.

Indexed as

Idiopathic Pulmonary FibrosisLung TransplantationFibrosisHumansTreatment Outcomeinterstitial lung diseasepulmonary fibrosissurgerytyrosine kinasewound healing

Identifiers

PMID37073794
PMCPMC10126649
OpenAlexW4366351092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.